Trial Profile
AZD9291 in EGFR exon 20 insertion mutations
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AEX20
- 06 May 2021 Status changed from active, no longer recruiting to completed.
- 10 Apr 2021 Results (n=12; Feb 2020) assessing efficacy in patients enrolled in stage 1 of this trial presented at the 112th Annual Meeting of the American Association for Cancer Research
- 28 Sep 2020 Planned End Date changed from 31 May 2021 to 31 Dec 2020.